Bottom line The one-week half-life of Ozempic explains why you must wait at least one week before taking the next dose or switching to an alternative GLP-1 agonist
The Bridge is CMSs way of opening access without rewriting that rule: it sits outside the normal Part D benefit, so individual drug plans dont carry the financial risk for these prescriptions
OMeara E, McDonald M, Chan M, et al
Eligible Medicare patients pay as little as a $50 copay for FDA-approved GLP-1s, or $140/month for compounded medications
Peptide Semaglutide B6/BPC-157 is a compounded therapeutic combination of three unique agents: Semaglutide a GLP-1 receptor agonist that was initially developed to manage type 2 diabetes, but is now used for weight loss, is gaining attention
One study presented at AAOS 2026 Annual Meeting found GLP-1s may help improve postoperative outcomes after certain orthopedic procedures